Exercise Intensity on Brain & Mental Health in Stress (ExStress)

February 5, 2024 updated by: Maria Ekblom, The Swedish School of Sport and Health Sciences

Acute Effects of Physical Exercise of Different Intensities on Biological and Psychological Outcomes Under Subclinical Stress and in Health

This study aims to examine the role of exercise intensity in the acute effects of a single bout of aerobic exercise on neurotrophic factors, biomarkers of stress and inflammation, working memory task-related changes in prefrontal cortex oxygenation in adults with stress-related symptoms, and matched healthy controls.

Study Overview

Detailed Description

This study will include 43 adult (20 - 40 years) participants experiencing stress-related symptoms and 43 healthy controls, matched by age, sex, and fitness. It will be a matched-pair (individuals with stress-related symptoms versus matched healthy controls) randomized-order crossover experimental trial with three experimental conditions separated by a wash-out period of 7 days: 20-min leg cycling exercise at moderate intensity, 20-min leg cycling exercise at vigorous intensity, and 20-min seated rest (passive control condition).

Prior to entering the study, study inclusion/exclusion criteria will be controlled using digital screening. Before the experimental sessions, all participants will complete two introductory study visits. At the first introductory visit, the participant's maximal oxygen uptake (VO2max) will be determined using a fitness test. This information will be used to determine the individual workloads (% of individual VO2max) that the participant will be cycling at during the experimental sessions, as well as for matching the two participant groups for fitness level. At the second introductory visit, participants will complete a familiarization session, in which key methodological aspects of the study will be introduced to participants. Participants' augmentation index, as a measure of arterial stiffness, will also be completed during this visit.

In each of the three experimental sessions, participants will perform a computerized working memory task (n-back task) pre- and post-exercise (or seated rest). During the working memory task, functional near-infrared spectroscopy (fNIRS) will be used to measure task-related changes in prefrontal cortex oxygenation. As such, each participant will complete six fNIRS measurements, two measurements (pre, post) for each of the three experimental sessions (moderate, high, control). Simultaneous with the fNIRS measurements, blood flow velocity in the left and right middle cerebral artery will be assessed during the n-back tasks using Transcranial Doppler ultrasound. At each experimental session, blood will also be sampled from the antecubital vein at seven time points: pre and post the first n-back task, pre and post the cycling exercise (or seated rest), pre and post the second n-back task, and post the final 10-min seated rest. Whole blood samples will be assessed for blood gases, acid-base status, electrolytes, hematocrit level, platelet count, and glucose. The separated blood plasma and serum samples will be used for measurements of neurotrophic factors, lactate, biomarkers of stress and inflammation, and factors involved in blood glucose control. Blood samples will also be used for targeted DNA screening for alleles of the BDNF.

Additionally, the participant's current mood, mental and physical fatigue, heart rate variability (HRV) and blood pressure will be assessed during four 10-min seated rest periods: pre and post n-back, and pre and post cycling exercise (or seated rest). Prior to each experimental study session, participants will have assessments of sleep quality the night before, current health status, physical activity level during the week prior to the test day, sleepiness level the last 10 min, and current mood. Participant's sleep quality and heart rate variability during the night before and after each experimental session will also be assessed.

Study Type

Interventional

Enrollment (Estimated)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

For participants both with and without stress-related symptoms:

  • Age: 20-40 years
  • Absence of contraindications to physical exercise
  • Do not participate in any other study

For participants with stress-related symptoms:

• Total score on the self-assessment scale 4-factor Shirom-Melamed Burnout Measure-19 greater than or equal to 2.95 but lower than 4.00

For healthy controls:

• Total score on the self-assessment scale 4-factor SMBM-19 lower than or equal to 2.21

Exclusion Criteria:

For participants both with and without stress-related symptoms:

  • Medical contraindication to catheterization of the antecubital vein and blood sampling
  • Dementia
  • Alcohol abuse
  • Smoking
  • Chronic medication that is considered to affect study outcomes
  • Chronic disease/syndrome such as migraine, fibromyalgia, chronic fatigue syndrome, bipolar syndrome, high blood pressure, cardiovascular disease, chronic obstructive pulmonary disease (COPD) or other lung disease
  • Post-COVID
  • Other somatic diseases, disorders, or injuries that may affect the physical ability during physical exercise

Exclusively for healthy controls:

• Depression (HAD depression score < 8) and anxiety (HAD anxiety score < 8)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Seated rest
Participants will be resting while seated on a comfortable chair for 20 minutes
Participants will be resting while seated on a comfortable chair for 20 minutes
Experimental: Exercise at moderate intensity
Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
Experimental: Exercise at vigorous intensity
Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in cerebral blood flow in prefrontal cortex
Time Frame: from before to after 20 minutes of exercise or seated rest
working memory task-related changes in prefrontal cortex oxygenation measured using functional near-infrared spectroscopy
from before to after 20 minutes of exercise or seated rest

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brain-derived neurotrophic factor
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
pro and mature BDNF in blood sample taken from the forearm antecubital vein; concentrations measured in blood plasma and serum
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Working memory performance
Time Frame: At one time point before and one time point after 20 minutes of exercise or seated rest (In total over 1 hour)
computerized working memory task (n-back: 1-, 2- and 3-back)
At one time point before and one time point after 20 minutes of exercise or seated rest (In total over 1 hour)
DNA allele of brain-derived neurotrophic factor
Time Frame: At one time point at baseline
in blood sample taken before intervention from the forearm antecubital vein
At one time point at baseline
Platelet count
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Cortisol
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
biomarker of stress; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Epinephrine
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
biomarker of stress; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Norepinephrine
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
biomarker of stress; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
C-reactive protein (CRP)
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Interleukin 6 (IL-6)
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Tumor necrosis factor alpha (TNF-α)
Time Frame: At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
as a measure of systemic inflammation; in blood sample taken from the forearm antecubital vein
At three time points before and four time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Mood
Time Frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
measured with a short version of Positive and Negative Affect Schedule (PANAS-SF) that include 5 positive and 5 negative affect states; the scoring scale is from 1 (very slightly or not at all) to 5 (extremely)
At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Mental fatigue
Time Frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
measured using Visual Analogue Scale (VAS-F); scoring scale: a line with 100 mm in length with scores falling between 0 mm (extremely alert) and 100 mm (extremely tired)
At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Physical fatigue
Time Frame: At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
measured using Borg Rating of Perceived Exertion scale; scoring scale: from 6 (no exertion) to 20 (maximal exertion)
At two time points before and two time points after 20 minutes of exercise or seated rest (In total over 2 hours)
Sleep quality
Time Frame: Over the night before and the night after each experimental session (In total over 36 hours)
measured using a Single-Item Sleep Quality Scale; scoring scale is from 0 (terrible) to 10 (excellent)
Over the night before and the night after each experimental session (In total over 36 hours)
Sleepiness
Time Frame: At single time point before 20 minutes of exercise or seated rest
measured using Karolinska Sleepiness Scale; scoring scale is from 1 (extremely alert) to 9 (extremely sleepy)
At single time point before 20 minutes of exercise or seated rest
Heart rate variability
Time Frame: Over the night before and the night after each experimental session (In total over 36 hours)
as an additional indicator of stress-related symptoms; measured with heart rate sensor and monitor
Over the night before and the night after each experimental session (In total over 36 hours)
Augmentation index
Time Frame: At a single time point at baseline
as a measure of arterial stiffness and indicator of cardiovascular health
At a single time point at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maria Ekblom, PhD, The Swedish School of Sport and Health Sciences (GIH)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2024

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

January 28, 2024

First Submitted That Met QC Criteria

February 5, 2024

First Posted (Actual)

February 7, 2024

Study Record Updates

Last Update Posted (Actual)

February 7, 2024

Last Update Submitted That Met QC Criteria

February 5, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2022-07297-01
  • 2023-08181-02 (Other Identifier: Swedish ethical review authority)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no current plan to make individual participant data available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Adults

Clinical Trials on Seated rest

3
Subscribe